
    
      Eligibility criteria

        1. Understand and voluntarily sign an informed consent form.

        2. Age 18 years at the time of signing the informed consent form.

        3. Able to adhere to the study visit schedule and other protocol requirements.

        4. Diagnosis of low- or intermediate-1-risk IPSS (see Appendix III) MDS without an
           abnormality of chromosome 5 involving a deletion between bands q31 and q33.

           Pathologic diagnosis via pathology performed at Rush University Medical Center or made
           available to Rush from outside institution.

        5. Prior treatment with < 3 cycles (84 days) of Revlimid® (lenalidomide) are eligible for
           enrollment regardless of response.

        6. ECOG performance status of 2 at study entry (see Appendix II).

        7. Disease free of prior malignancies for > 5 years with exception of currently treated
           basal cell, squamous cell carcinoma of the skin, or carcinoma "insitu" of the cervix or
           breast.

        8. Serum bilirubin levels < 1.5 times the upper limit of the normal range for the
           laboratory (ULN). Higher levels are acceptable if these can be attributed to active
           hemolysis or ineffective erythropoiesis.

        9. Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or
           serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) levels < 2 x
           ULN.

       10. Serum creatinine levels < 1.5 x ULN

       11. Absolute neutrophil count > 1000/mm³

       12. Platelet count > 30,000/mm³

       13. All study participants must be registered into the mandatory RevAssist® program, and be
           willing and able to comply with the requirements of RevAssist®.
    
  